1)Spaide RF, Fisher YL:Intravitreal bevacizumab(Avastin)treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275-278, 2006
2)Ahmadieh H, Entezari M, Monshizadeh R et al:Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients. A randomized clinical study. Ophthalmology 116:1943-1948, 2009
3)Avery RL, Wendel R, Patel A et al:Intravitreal bevacizumab(Avastin)in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695, e1-15, 2006
4)Ishikawa K, Takahara Y, Negi A et al:Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 23:108-111, 2009
5)Rizzo S, Genovesi EF, Di Bartolo E et al:Injection of intravitreal bevacizumab(Avastin)as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy(PDR). Graefes Arch Clin Exp Ophthalmol 246:837-842, 2008
6)Lo WR, Martin DF, Hubbar Ⅲ GB et al:Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab(Avastin). Retina 29:926-931, 2009
7)Yang CM, Yang CH, Chan MS et al:Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 146:211-217, 2008
8)Arevalo JF, Berrocal MH, Sanchez JG et al:Tractional retinal detachment following intravitreal bevacizumab(Avastin)in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213-216, 2008
9)Hurwitz H, Fehrenbacher L, Novotny W et al:Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
10)Mak KH, Moliterno DJ, Granger CB et al:Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiology 30:171-179, 1997